Applications

Reproducible, predictable gene delivery.

Precision Plasmids are designed for any program that depends on a gene being present, at a defined copy number, for as long as the product needs it. That begins with plasmid DNA and biologics manufacturing, extends into protein discovery and reaches, with partners, into cell and gene therapy, regenerative medicine, transformation of exotic production organisms and the far reaches of biology that will become tomorrow’s biotech frontiers.

One platform at the center, widening through three application areas: manufacturing now, discovery next, and therapy with partners ONE PLATFORM NOW · MANUFACTURING NEXT · DISCOVERY WITH PARTNERS · THERAPY

Three application areas

Now

First products

Plasmid DNA manufacturing

  • High-copy E. coli production strains
  • Targeting an order-of-magnitude gain in yield per cell and per unit production volume
  • A drop-in improvement with no new regulatory pathway

ForPlasmid DNA manufacturers and CDMOs

Next

Platform expansion

Biologics manufacturing and protein discovery

  • Precision Plasmids for CHO and microbial protein expression
  • Copy number as a set point, not a screening outcome
  • High rates of inheritance, high genetic stability
  • Faster, more predictable cell line development

ForBiologics manufacturers, discovery teams and AI protein-design platforms

With partners

Therapeutic programs

Cell and gene therapy and vaccines

  • Regenerative medicine
  • Non-integrating, non-viral, re-dosable delivery
  • Flexible payloads, from single genes to large, multi-gene pathways with no ceiling
  • Developed with partners on human-cell data

ForCell and gene therapy and vaccine developers

Why now

Two forces are converging to increase the attractiveness of non-viral gene delivery.

One pushes demand away from viral vectors. The other provides the industry with more powerful tools for designed biology.

The push

Viral vectors are under pressure.

  • Regulators have sharpened their scrutiny of AAV safety after multiple serious adverse events seen in AAV clinical trials in 2024 to 2026.
  • Viral-vector manufacturing is costly and capacity-constrained. Besides adverse events, manufacturing issues are a leading cause of gene therapy clinical delays.
  • Pharma has recognized the shift away from viruses and is already licensing and acquiring non-viral delivery technology.
The pull

AI now designs biology faster than it can be put to practice.

  • Protein and antibody design platforms generate candidates far faster than those candidates can be expressed, screened and manufactured.
  • The bottleneck has moved downstream: getting a gene into a cell at a predictable copy number, stably enough to make.
  • Every AI-first discovery platform needs an expression and delivery layer that scales with its output.
  • Delivery needs to be reproducible and predictable for discovery and expression screening datasets to be reliable.

Tell us about your challenges with gene delivery or gene expression